JPS6237614B2 - - Google Patents
Info
- Publication number
- JPS6237614B2 JPS6237614B2 JP56112856A JP11285681A JPS6237614B2 JP S6237614 B2 JPS6237614 B2 JP S6237614B2 JP 56112856 A JP56112856 A JP 56112856A JP 11285681 A JP11285681 A JP 11285681A JP S6237614 B2 JPS6237614 B2 JP S6237614B2
- Authority
- JP
- Japan
- Prior art keywords
- protease
- acidic protease
- acidic
- cells
- antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000259 anti-tumor effect Effects 0.000 claims description 8
- 108091005508 Acid proteases Proteins 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 13
- 239000004365 Protease Substances 0.000 description 13
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 229940100618 rectal suppository Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710180316 Protease 2 Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- -1 inhaler Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56112856A JPS5813523A (ja) | 1981-07-18 | 1981-07-18 | 抗腫瘍作用を有する医薬組成物 |
| CA000395742A CA1181005A (en) | 1981-02-10 | 1982-02-08 | Therapeutic agent for treatment of allergic diseases, immune complex diseases and tumors |
| AU80290/82A AU531314B2 (en) | 1981-02-10 | 1982-02-09 | Therapeutic agent containing human urinary acid protease |
| SE8200748A SE455163B (sv) | 1981-02-10 | 1982-02-09 | Uropepsin for anvendning som terapeutikum mot allergiska sjukdomar, immunkomplexsjukdomar och tumorer |
| GB8203682A GB2095993B (en) | 1981-02-10 | 1982-02-09 | Compositions containing human urinary acid protease |
| CH782/82A CH653557A5 (de) | 1981-02-10 | 1982-02-09 | Zur behandlung von allergischen zustaenden, immunkomplexkrankheiten und tumoren geeignetes therapeutisches mittel. |
| FR8202145A FR2499409A1 (fr) | 1981-02-10 | 1982-02-10 | Agent therapeutique a base d'une protease acide, pour le traitement des troubles allergiques, des maladies avec immunocomplexe et des tumeurs |
| NL8200509A NL8200509A (nl) | 1981-02-10 | 1982-02-10 | Geneesmiddel voor allergiekwalen, immuuncomplexziekten en tumoren; werkwijze voor het behandelen van patienten die hieraan lijden. |
| IT47761/82A IT1154280B (it) | 1981-02-10 | 1982-02-10 | Agente terapeutico a base di protea si acida e suo impiego in pazienti affetti da disordini allergici,malattie da immuno-complessi e tumori |
| DE8282100973T DE3273953D1 (en) | 1981-02-10 | 1982-02-10 | Therapeutic agent containing a human urinary pepsin |
| DE19823204631 DE3204631A1 (de) | 1981-02-10 | 1982-02-10 | Therapeutisches mittel und dessen verwendung |
| EP82100973A EP0059346B1 (en) | 1981-02-10 | 1982-02-10 | Therapeutic agent containing a human urinary pepsin |
| US06/365,465 US4540569A (en) | 1981-02-10 | 1982-04-05 | Method for treatment of allergic disorders and immune complex diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56112856A JPS5813523A (ja) | 1981-07-18 | 1981-07-18 | 抗腫瘍作用を有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5813523A JPS5813523A (ja) | 1983-01-26 |
| JPS6237614B2 true JPS6237614B2 (en]) | 1987-08-13 |
Family
ID=14597240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56112856A Granted JPS5813523A (ja) | 1981-02-10 | 1981-07-18 | 抗腫瘍作用を有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5813523A (en]) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0676339B2 (ja) * | 1985-09-13 | 1994-09-28 | 浩 前田 | 制癌剤 |
-
1981
- 1981-07-18 JP JP56112856A patent/JPS5813523A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5813523A (ja) | 1983-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Burger et al. | Human plasma R-type vitamin B12-binding proteins. II. The role of transcobalamin I, transcobalamin III, and the normal granulocyte vitamin B12-binding protein in the plasma transport of vitamin B12. | |
| Kimelberg et al. | The effect of entrapment in liposomes on the in vivo distribution of [3H] methotrexate in a primate | |
| CA1120468A (en) | Hgi-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same | |
| EP3061452B1 (en) | Icaritin for use in preventing or treating hematocytopenia | |
| JPH0629194B2 (ja) | 悪性腫瘍性貧血治療剤 | |
| EP3773686B1 (en) | Alkaline phosphatase agents for treatment of radiation disorders | |
| WO2020211009A1 (zh) | 痘苗病毒致炎兔皮提取物治疗造血系统损伤的用途 | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| CN119405790A (zh) | 胰酶联合灵芝在制备治疗白细胞减少的药物中的用途 | |
| JPS6237614B2 (en]) | ||
| CN114224934B (zh) | 一种改善微循环的杜仲提取物 | |
| CN100493522C (zh) | 一种苦参素和多糖的药物组合物 | |
| Owen et al. | A phase I clinical evaluation of liposome-entrapped doxorubicin (Lip-Dox) in patients with primary and metastatic hepatic malignancy | |
| JP2020537689A (ja) | Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
| EP0100366A1 (en) | Agent for treating allergic disease, immunity complex disease, and tumour | |
| NL8200509A (nl) | Geneesmiddel voor allergiekwalen, immuuncomplexziekten en tumoren; werkwijze voor het behandelen van patienten die hieraan lijden. | |
| JPS5995221A (ja) | 食細胞機能調節作用を有する医薬組成物 | |
| JPH01203334A (ja) | 白金を含有する薬剤の副作用軽減剤 | |
| US4591504A (en) | Human leucocyte pepsin-like enzyme as a therapeutic agent for treating allergic disorders and immune complex diseases | |
| EP1210944A1 (en) | Blood plasma replacement solution | |
| CN104645334A (zh) | N-乙酰半胱氨酸活性炭组合物及其制备方法和应用 | |
| JPWO2020092523A5 (en]) | ||
| RU2166944C2 (ru) | Плазмозамещающий раствор с гемокоррегирующими и иммуномодулирующими свойствами | |
| JPS6237612B2 (en]) | ||
| CN118078995A (zh) | 一种双重靶向高水溶性小分子硼药及其制备方法和应用 |